Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Annovis Bio has commenced the treatment of first two subjects in a randomised Phase III clinical trial to assess the efficacy and safety of buntanetap in treating early Alzheimer's disease (AD). The ...

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Funded by a one-year, $500,000 grant from the National Institutes of Health (NIH)’s AIM AHEAD program, the researchers are ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, potentially improving survival and expanding treatment options. A novel approach ...

Funded by a one-year, $500,000 grant from the National Institutes of Health (NIH)’s AIM AHEAD program, the researchers are developing an AI-powered network to advance health care and health-related ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...